Not So Different: a Podcast from The Center for Biosimilars

To listen to part 1 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-biosimilar-companies-are-stepping-up-their-game-to-compete-against-originators].To listen to part 2 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-1-practice-is-addressing-biosimilar-concerns-over-savings-safety-and-efficacy].To learn more about building patient confidence in biosimilars, click here [https://www.centerforbiosimilars.com/view/what-should-educational-materials-include-to-instill-confidence-in-biosimilars-].To learn more about how education can improve patient confidence, click here [https://www.centerforbiosimilars.com/view/report-physician-patient-education-can-improve-biosimilar-acceptance].

To listen to part 1 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-biosimilar-companies-are-stepping-up-their-game-to-compete-against-originators]. To learn more about building physician confidence in biosimilars, click here [https://www.centerforbiosimilars.com/view/gary-lyman-md-details-what-needs-to-be-done-to-ensure-physician-confidence-in-biosimilars]. For more on how switching to biosimilars can  impact budgets and savings, click here [https://www.centerforbiosimilars.com/view/budget-model-predicts-savings-for-switch-to-rituxumab-biosimilar-in-nhl-cll].

Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market. We sat down with Kirollos Hanna, PharmD, the manager of Oncology Pharmacy at the University of Minnesota Medical Center, an associate editor for the Journal of the Advanced Practitioner in Oncology, and an assistant professor at the Mayo Clinic School of Medicine, to discuss what tactics biosimilar companies are using to better compete alongside originator manufacturers.

A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice. We sat down with Gary Lyman, MD, MPH, an oncologist, hematologist, public health researcher, and long-time biosimilar advocate who has also helped develop guidelines in support of using biosimilars in the oncology space. We discussed what steps are needed to improve physician confidence in using biosimilars.

To hear more from Paul on biosimilar issues, click here [https://www.centerforbiosimilars.com/view/part-1-panelists-suggest-more-groundwork-is-needed-for-indian-biologics-to-achieve-global-market-access] or here [https://www.centerforbiosimilars.com/view/part-2-panelists-advise-patterning-guidelines-on-international-standards].To read about Paul’s insight on the current issues in the Indian biosimilar market, click here [https://www.centerforbiosimilars.com/view/column-india-struggles-to-meet-international-biologics-standards].